(HealthDay News) — High-intensity focused ultrasound seems superior to other therapies for pancreatic cancer, according to a review published in the December issue of the Journal of Evidence-Based Medicine.

Cui Cui Li, from the West China Hospital of Sichuan University in Chengdu, and colleagues conducted a systematic review and meta-analysis to explore the efficacy and safety of high-intensity focused ultrasound combined with other physical therapies for the treatment of pancreatic cancer. Data were included from 23 studies involving 19 randomized controlled trials and four clinical controlled trials.

The researchers found that the survival rate at six and 12 months, overall efficacy, and clinical benefit rate were significantly higher in the high-intensity focused ultrasound plus radiation and chemotherapy group than in the three-dimensional conformal radiation therapy, gemcitabine, gemcitabine plus cisplatin, and gemcitabine plus 5-fluorouracil groups (all P<0.05). The adverse effects were similar in the high-intensity focused ultrasound plus other therapy and the control group. Skin damage and fever were the major high-intensity focused ultrasound-related adverse effects.

“The current evidence suggested that the efficacy of high-intensity focused ultrasound for pancreatic cancer was superior to other therapies,” the authors write. “However, the poor quality of [trials] may reduce the reliability of outcome to some extent.”

Full Text (subscription or payment may be required)